2023 Chinese guideline for lipid management

Frontiers in Pharmacology

Pharmacology

Sheng-Kai Yan¹  Jing Liu²  Dong Zhao²  Jian-Jun Li³  Run-Lin Gao³  Na-Qiong Wu³  Zeng-Wu Wang³  Yuan-Lin Guo³  Guo-Ping Lu⁴  Zhen-Yue Chen⁴  Dao-Quan Peng⁵  Shui-Ping Zhao⁵ 

[1] Affiliated Hospital of Zunyi Medical University, School of Laboratory Medicine of Zunyi Medical University, Zunyi, Guizhou, China;Beijing Anzhen Hospital, Capital Medical University, Beijing, China;National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China;Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;The Second Xiangya Hospital of Central South University, Changsha, Hunan, China;

关键词: atherosclerosis;    cardiovascular disease;    lipid;    management;    statin;    combined therapy;   

DOI  :  10.3389/fphar.2023.1190934

 received in 2023-03-21, accepted in 2023-06-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the “Guidelines for the prevention and treatment of dyslipidemia" were adapted into the “Chinese guideline for Lipid Management" (henceforth referred to as the new guidelines) by an Experts’ committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with cardiovascular disease (CVD) risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.

【 授权许可】

Unknown   
Copyright © 2023 Li, Zhao, Zhao, Lu, Peng, Liu, Chen, Guo, Wu, Yan, Wang and Gao.